New drug cocktail aims to stop myeloma in its tracks

This phase 3 trial is testing whether adding an experimental drug called SCTC21C to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) can help people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The study will enroll 292 participants and measure how long the cancer stays under control and whether cancer cells become undetectable. The goal is to improve outcomes without requiring lifelong treatment, though ongoing monitoring will still be needed.